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RÉSUMÉ 
Introduction: Le supplément d’oxygène et la nutrition parentérale (NP) sont les deux 
sources majeures de stress oxydant chez le nouveau-né. Lors de la détoxification des 
oxydants, le potentiel redox du glutathion s’oxyde. Notre hypothèse est que le 
supplément d’oxygène et la durée de la NP sont associés à un potentiel redox plus 
oxydé et à une augmentation de la sévérité de la dysplasie bronchopulmonaire (DBP). 
Patients et Méthodes: Une étude observationnelle prospective incluant des enfants de 
moins de 29 semaines d’âge gestationnel. Les concentrations sanguines de GSH et 
GSSG à jour 6-7 et à 36 semaines d’âge corrigé étaient mesurées par électrophorèse 
capillaire et le potentiel redox était calculé selon l’équation de Nernst. La sévérité de 
la DBP correspondait à la définition du NICHD.  
Résultats: Une FiO2≥ 25% au 7ième jour de vie ainsi que plus de 14 jours de NP sont 
significativement associés à un potentiel redox plus oxydé et à une DBP plus sévère. 
Ces relations sont indépendantes de l’âge de gestation et de la gravité de la maladie 
initiale. La corrélation entre le potentiel redox et la sévérité de la DBP n’est pas 
significative. La durée de la NP était responsable de 15% de la variation du potentiel 
redox ainsi que de 42% de la variation de la sévérité de la DPB.  
Conclusion: Ces résultats suggèrent que l’oxygène et la NP induisent un stress 
oxydant et que les stratégies visant une utilisation plus judicieuse de l’oxygène et de 
la NP devraient diminuer la sévérité de la DBP. 
Mots clés: enfants prématurés, oxygène, alimentation parentérale, stress oxydant, 
potentiel redox, dysplasie bronchopulmonaire.  
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ABSTRACT 
Introduction: oxygen supplementation and total parenteral solution (TPN) are two 
main clinical practices that sustain oxidative stress. Glutathione is a key molecule that 
detoxifies peroxides resulting in a more oxidized redox potential. We hypothesize 
that O2 supplementation and longer TPN duration are associated with both more 
oxidized redox potential and more severe bronchopulmonary dysplasia (BPD). 
Patients and methods: A prospective observational study including infants of less 
than 29 weeks gestational age. GSH and GSSG from whole blood sampled on day 6-
7 and at 36 weeks of corrected age (CA) were measured by capillary electrophoresis 
and redox potential was calculated using Nernst equation.  BPD was classified 
according to NICHD guidelines.  
Results: There was a significant association between FiO2 ≥ 25% on day 7 of life and 
TPN duration longer than 14 days and both more oxidized redox potential and more 
severe BPD.  TPN duration explained both 15 % of total variation observed in redox 
potential and 42 % of total variation in BPD severity. These associations remained 
significant after adjustment for gestational age and illness severity. The relation 
between the severity of BPD and the redox potential in blood was not significant. The 
statistic power (1-β) to show an effect of redox potential on severity of BPD was 
52%. 
Conclusion: Both redox potential of glutathione and BPD severity are both associated 
with early O2 supplement and TPN. Strategies targeting judicious use of O2 
V 
supplement and either decreasing the duration or using safer formulation of TPN are 
expected to help reducing BPD.  
Keywords: premature infants, oxygen, total parenteral nutrition, oxidative stress, 
redox potential, and bronchopulmonary dysplasia. 
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I.A. Prematurity 
I.A.1. The number of premature infants is in constant increase 
 The report issued by Canadian Institute of Health Information (CIHI) in May 2011, 
indicated an increase of 38000 births (which represent 10.2% ) in 2009-2010 
compared to 2004-2005 (1). This increase of total number of births was associated 
with a steady increase in preterm birth rate from approximately 6% in the early 1980 
(2) to 8% in recent years (1).  
I.A.2. Increasing survival of extreme preterm infants and 
bronchopulmonary dysplasia 
Advances in perinatal and neonatal medicine over the last few decades resulted in 
marked increase in the survival of infants less than 29 weeks of gestational age (3). In 
a recent study including 355 806 infants with birth weight of 501 to 1500 g and who 
were born in 2000–2009, mortality rate decreased from 14.3% to 12.4% (4). Survival 
of these vulnerable infants led to increased incidence of prematurity related diseases. 
Bronchopulmonary dysplasia (BPD) is currently the most common chronic lung 
disease in infancy and carries extremely high costs (5). 
I.B. Bronchopulmonary dysplasia (BPD) 
I.B.1. Clinical definitions of BPD:  
The definition of BPD has changed overtime in the literature. The most important 
definitions will be presented chronologically in the following section:  
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Original definition for BPD diagnosis: A U.S. National Institutes of Health 
(NIH) workshop held in 1979 proposed this BPD definition “continued oxygen 
dependency during the first 28 days plus compatible clinical and radiographic 
changes” (6). 
Traditional (classic) definition: Instead of the original definition, Shennan et 
al. (7) suggested a more accurate predictor of BPD to be, “the requirement for 
additional oxygen at a corrected postnatal gestational age of 36 weeks in infants less 
than 1,500 g of birth weight”. This definition appears to also predict pulmonary 
outcome among infants with the “new” BPD (8). 
 Severity definition: the joint National Institute of Child Health & Human 
Development (NICHD)-National Heart, Lung, and Blood Institute (NHLBI) 
workshop defined mild, moderate and severe BPD according to specific criteria (9) 
(table I).  
In a validation study, the NICHD–NHLBI workshop definition accurately 
predicted pulmonary outcomes including percent of patients needing treatment with 
pulmonary medications and rehospitalization for pulmonary causes (10). 
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Table I. NICHD classification of BPD diagnosis and severity for infants less 
than 32 weeks of GA: 
Treatment with oxygen 21% for at least 28 d plus 
Mild BPD Breathing room air at 36 weeks PMA or discharge, 
whichever comes first 
Moderate BPD Need for < 30% oxygen at 36 weeks PMA or discharge, 
whichever comes first 
Severe BPD Need for ≥ 30% oxygen and/or positive pressure at 36 
weeks PMA or discharge, whichever comes first 
 
Physiological definition: all previous definitions has an inherent limitation, 
that is the need for oxygen is determined by individual physicians or nursing staff 
rather than on a physiologic assessment. Accordingly, the physiological definition 
determined BPD at 36 weeks of correct age as follows, First:  neonates on positive 
pressure support or receiving > 30% supplemental oxygen with saturations between 
90% and 96% were assigned the outcome BPD and not tested further. Second, those 
receiving < 30% oxygen or effective oxygen > 30% with saturations > 96% 
underwent a room-air challenge with continuous observation and oxygen-saturation 
monitoring. Outcomes of the room-air challenge were “no BPD” (saturations > 90% 
during weaning and in room air for 30 minutes) or “BPD” (saturation < 90%) (11). 
The NICHD neonatal network centers’ study demonstrated that many babies who, 
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according to the nursing staff, required oxygen were able to maintain a SaO2 > 90% 
on room air. In this study, though 560 (35%) had clinical BPD (oxygen use at 36 
weeks), only 398 (25%) had physiological BPD (12). 
I.B.2. Incidence of BPD 
BPD is the most prevalent and one of the most serious long-term sequelae of preterm 
birth (13). Variation in reported rates is well documented. Among 4213 infants born 
in 2003 at 24–31 weeks’ gestation in 10 different European regions, the rate of BPD 
(oxygen requirement at 36 weeks’ PMA) was anywhere from 10.5% to 21.5% (14). 
In 2010, the Neonatal Research Network report on neonatal outcomes of extremely 
preterm infants assessed 9575 infants born at extremely low gestational ages (22–28 
weeks) and very low birth weights (401–1500 g) at network centers between January 
1, 2003 and December 31, 2007. The incidence of BPD as determined by the 
severity-based definition was 68% -Including babies with mild BPD- (oxygen therapy 
for 28 days but use of room air at 36 weeks); it was down to 42% if using the 
traditional definition and 40% if using the physiologic definition. In the same cohort, 
the incidence of BPD is largely affected by the gestational age with an incidence of 
85% of infants born at 22 weeks’ gestation vs. 23% of those born at 28 weeks’ (15). 
I.B.3. Normal lung development and the effect of timing of lung injury 
Human lung development proceeds in five regulated stages: embryonic (3–7 weeks’ 
gestation), pseudoglandular (7–17 weeks’), canalicular (17–27 weeks’), saccular (28–
36 weeks’) and alveolar and microvascular maturation (36 weeks’ gestation to at least 
2 years after birth) (16, 17). The lungs of preterm infants born at 24–28 weeks’ 
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gestation are in the late canalicular and transitioning to early saccular stages; 
therefore cannot support efficient gas exchange. Branching and expansion of air 
spaces to form saccules and thinning of mesenchyme occur later in gestation, as do 
the formation of alveoli and the synthesis of surfactant by type II alveolar cells which 
only commence in late gestation (16, 17). Alveolarization, the final stage of lung 
development, begins in the near-term lung before birth, but primarily occurs 
postnatally, during the first 2–3 years of life, and may continue at a slower rate 
beyond childhood (18). Any injury to the lung at the early stages of development can 
potentially alter the developmental process, leading to long-term pulmonary sequelae 
(19). 
I.B.4. Pathogenesis of BPD 
Different patterns of pulmonary damage to immature lung may occur as a result of 
many different potentially harmful factors. The pattern of damage depends on the 
extent, timing and duration of the exposure to such factors (5). “Old” BPD was 
described in late preterm infants who were exposed to aggressive ventilation and 
excessive O2 supplement (20).  This pattern of lung injury was associated with 
prominent interstitial fibrosis, alveolar overdistention alternating with regions of 
atelectasis, and airway abnormalities such as squamous metaplasia and excessive 
muscularization. On the other hand, the “new” BPD, occurring in extremely 
premature infants, shows histological features consistent with developmental arrest 
and impaired alveolar development  including decreased alveolarization and 
diminished and dysmorphic platelet endothelial cell adhesion molecule staining (21). 
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Alveoli are fewer in number and larger in diameter than normal; the fibrosis, 
squamous metaplasia and excessive airway muscularization seen in classical BPD are 
conspicuously absent; airway and microvascular growth are affected (22). In 2001, 
the ‘vascular hypothesis’ was described by Abman (23). Vascular endothelial growth 
factor (VEGF) is involved in angiogenesis. It was found to have impaired signaling 
and thus thought to play a role in the development of BPD in a preterm baboon model 
(24) as well as in human infants (25). The work of Van Tuyl et al adds additional 
insight to the understanding of the epithelial vascular interaction and the importance 
of the fetal hypoxic state for lung development (26). In this lung explant model, 
exposure to low oxygen (3% O2) enhanced both epithelial branching morphogenesis 
and vascular development compared to 20% O2, with more complex epithelial and 
vascular branching. VEGF mRNA was also dramatically increased in explants 
exposed to 3% O2. This study lends credence to the current concept that even room 
air (21% O2) is likely toxic to the developing lung and that this "relative hyperoxia" 
inhibits both pulmonary vascular development and epithelial branching 
morphogenesis (26). 
The etiology of BPD continues to be recognized as a multifactorial.  Major etiological 
factors include prematurity, mechanical ventilation and lung trauma, oxygen 
supplement and sources of oxidative load like total parenteral nutrition (PN) as well 
as neonatal infection (27-31).  
Although the etiology of BPD is multifactorial, the concept of ‘pulmonary oxygen 
toxicity’ received additional support in the 1980s. In a series of papers, Saugstad 
promoted the concept that oxidative stress could result in the pulmonary damage 
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associated with BPD (27, 32, 33). This concept has continued to be supported, rather 
than refuted, in recent years. Oxidative stress and its relation to BPD will be 
discussed in the following sections. 
I.C. Oxidative stress  
Oxidative stress is classically defined as ‘an imbalance between oxidants and 
antioxidants in favor of the oxidants’ (34). Initially, research was concentrated on the 
chemistry of each oxidant and the damage it can inflict. In the 1980s, the idea that 
lower concentration of certain oxidants (superoxide and hydrogen peroxide) could 
induce cell division caused a scientific controversy (35). This idea of considering 
certain oxidants as an important component of normal biology and that they can act 
as signaling molecules is now established (36-39). The contemporary definition of 
oxidative stress has been refined to account for these two different mechanistic 
pathways of oxidative damage namely the macromolecular damage (caused mainly 
by radical oxidants) and the disruption of redox signaling (caused mainly by 
nonradical oxidants). This new definition considers oxidative stress as ‘an imbalance 
between oxidants and antioxidants in favor of the oxidants, leading to a disruption of 
redox signaling and control and/or molecular damage’ (39, 40). Biological systems 
was shown to generate more nonradical oxidants than free radicals than radical 
oxidants (41).  This can explain why free radical macromolecular damage can 
correlate with the pathological insult and be largely irrelevant to the disease process 
that is mainly caused by the nonradical oxidant burden (40).  
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I.D. Oxidants 
Oxidants are electron-accepting molecules in chemical reactions in which electrons 
are transferred from one molecule to another. Oxidants are formed as a normal 
product of aerobic metabolism but can be produced at elevated rates under 
pathophysiological conditions (34). They include both free radical as well as non-
radical oxidants. Molecules or ions formed by the incomplete reduction of oxygen are 
called reactive oxygen species (ROS). These reactive oxygen intermediates include 
singlet oxygen; superoxide; peroxides and hydroxyl radical. Free radical oxidants 
include the superoxide anion radical, hydroxyl radical and nitric oxide while 
nonradical oxidants include hydrogen peroxide, hydroperoxy fatty acids, aldehydes, 
quinines as well as peroxynitrites (40). Although these oxidant molecules can be 
derived from detoxification of xenobiotics, the main producer remains the oxidative 
phosphorylation in mitochondrion (42). Oxygen is easily reduced in water through 
the various protein complexes of mitochondrion. During these processes, about 1 % 
of O2 will be partially reduced, with generation of the radical oxidant superoxide 
anion (O2·-) (43). Superoxide dismutase (SOD) converts two superoxide anions into 
hydrogen peroxide (H2O2), nonradical oxidant, and oxygen (Figure I) (44) (45). The 
two electron, nonradical oxidant, H2O2 is produced at 1 to 4% of the rate O2 
consumption and therefore represent a major oxidant. H2O2 can be reduced by two 
enzymes, glutathione peroxidase (GPx) (46) or catalase into O2 and H2O (47). If not, 
H2O2 can react with Fe2+ forming the hydroxyl radical (·OH) via the Fenton reaction. 
This hydroxyl radical (·OH) is among the most reactive of molecules, leading to the 
oxidation of proteins, lipids and DNAs (Figure I).  
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 Figure I: Reactive oxygen species formation and the role of different 
antioxidant enzymes.  
I.D.1. Oxygen as an oxidant in preterm infants 
Birth is a major transition from relative hypoxic intrauterine environment where 
arterial pressure of O2 (PaO2) is around 25 mm Hg to oxygen rich extra-uterine 
environment with PaO2 around 75 mm Hg. This means that even 21% O2 is 
considered supra-physiologic for preterm infants and is associated with marked 
increase in total reactive oxygen species (ROS) burden (48). Many preterm infant 
will initially have respiratory distress caused by the immaturity of their lung 
surfactant system (known as hyaline membrane diseases), leading to the need of FiO2 
more than 21%. Greater oxygen load increases the concentration of dissolved oxygen 
available for oxidative phosphorylation in the mitochondria. Under conditions of 
hyperoxia, there is a marked increase in rate of ROS with increasing O2 tension. 
Under FiO2 of 95% there is a 10 fold increase of ROS comparing to ambient O2 
(21%) (49).  
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 I.D.2. Parenteral nutrition as an oxidant in preterm infants 
Parenteral nutrition allows administration of amino acids, dextrose, vitamins, 
electrolytes and lipids. Almost all preterm infants will need parenteral nutrition when 
enteral nutrition is not possible due to gastrointestinal immaturity, gastrointestinal 
pathology - like necrotizing enterocolitis - or with deterioration of general condition -  
like sever septicemia with ileus -. Interaction between reducers such as 
polyunsaturated fatty acids, several amino acids and vitamin C and a strong oxidant 
as dissolved oxygen generates oxidant molecules. These molecules include aldehydes 
and hydroperoxides derived from lipid peroxidation and hydrogen peroxide (H2O2) 
from ascorbic acid (50-52). All these molecules are detoxified by the glutathione 
system. In addition of the generation of these oxidants, these reactions contribute to 
the loss of fatty acids, amino acids and antioxidant vitamin such as ascorbate.  PN 
contains a photo-sensitive compound, riboflavin, this means that these reactions can 
be catalyzed by ambient light (51-53). Photoprotection of PN solutions was found to 
decreases the infused load as well as the urinary excretion of peroxides in premature 
infants (54). Adequate photoprotection of parenteral nutrition has also been reported 
to reduce the incidence of BPD in premature infants (55, 56). 
I.E. Antioxidant defenses 
 I.E.1. Definition and summary of different types of antioxidants 
‘All respiring organisms are caught in the cruel blind in that oxygen which support 
their lives is a toxic substance in whose presence they survive only by virtue of an 
elaborate system of defenses’ Irwin Fridovitch (born 1929) 
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Antioxidant can be defined as ‘any substance that when present at low concentration 
compared with that of an oxidizable substrate significantly delays or inhibits 
oxidation of that substrate’ (57). This definition was recently reviewed to include a 
wider range of antioxidant activity including the repair of any damage caused by 
oxidants, so the revised definition indicates that antioxidant is “any substance that 
delays, prevents or removes oxidative damage to a target molecule” (58).  
Antioxidants include both non-enzymatic as well as enzymatic compounds (Figure 
II). This diversity of antioxidants matches the diversity of oxidant molecules (34, 59). 
Superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase are the 
main components of enzymatic antioxidants (60). Extracellular SOD is produced by 
type II alveolar cells, airway epithelial cells, macrophages and endothelial cells (61). 
It is found in high concentration in human lung comparing to plasma and other organs 
(62).  Intracellular SOD includes CuZn-SOD located in the cytoplasm and 
peroxisome as well as Mn-SOD located in the mitochondria (63). SOD plays a very 
important role by reducing the free radical anion superoxide in oxygen and hydrogen 
peroxide that will be reduced in water by catalase or GPx (Figure I).  Catalase is 
present only in the peroxisome and, to a lesser extent, in mitochondria. In this major 
source of oxidants, GPx is more important than catalase for the reduction of hydrogen 
peroxide (60).  
Non enzymatic antioxidants include both fat soluble compounds like vitamin E (α - 
tocopherol) and β – carotene (precursor to vitamin A) as well as water soluble 
compounds like vitamin C, glutathione (GSH) and ceruloplasmin. 
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Vitamin E is incorporated into cell membranes where it protects them from the 
oxidative damage by scavenging free radicals resulting oxidized and inactive Vitamin 
E (64). Vitamin C (water soluble vitamin) is a strong reducing agent. It participates in 
a variety of oxido-reductive reactions and allows the recycling of the oxidized form 
of vitamin E into its reduced and active form (65). 
The oxidized form of vitamin C can be returned to the reducing form by the action of 
the glutathione system (66). In addition to the recycling of vitamins C and E, 
glutathione works as a co-factor of several enzymes, especially glutathione 
peroxidase and glutathione-S-transferase.  As glutathione is considered a key 
molecule in the antioxidant defenses of the organism, the next section is devoted to 
the glutathione. 
 
Figure II: summary of antioxidant compounds and enzymes. 
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I.E.2.Glutathione (GSH) as a main antioxidant 
Glutathione (γ-glutamylcysteinylglycine) has a key role in maintaining the redox 
environment as antioxidant (67, 68). GSH is the most prevalent cellular thiol and the 
most abundant low molecular-weight peptide present in cells. It is produced in large 
quantities in all cells and distributed into subcellular compartments: the cytosolic (1-
11 mM) in which GSH is synthesized, the nucleic (3-15 mM) where it maintains a 
functional redox state of DNA, and mitochondrial (5-11 mM) where the oxidative 
stress is high (38). By its abundance, glutathione is recognized as the main buffer of 
the cellular redox environment (38). 
 Reactive oxygen species such as peroxides are reduced by glutathione (GSH) 
resulting in an oxidized glutathione (GSSG). This results in a more oxidized redox 
environment in cells (Figure III).  
 
Figure III: Peroxides are reduced using the reduced glutathione leading to the 
formation of oxidized glutathione resulting in a more oxidized cell redox potential. 
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The redox potential of glutathione is dependent of the concentration of GSH and 
GSSG according to the Nernst equation: ΔE =ΔE°· (RT/nF)· log ([GSH]2/[GSSG]) 
(38).  Changes in the redox potential of glutathione can lead to important changes in 
redox signaling and cellular status as it will be described in the next section. 
I.E.3. Redox potential as physiologic regulators 
The redox potential acts as a switch for a number of metabolic pathways, inducing 
cellular proliferation, differentiation or apoptosis (38). 
 During organ development, cells must pass through the various cell cycle stages in 
order to allow for continued remodeling. This process is essential to proper lung 
development (69-71). The proliferation phase is accompanied by a higher metabolic 
rate leading to increased generation of ROS. These ROS in turn favor a shift of the 
redox potential toward a more oxidized status, inducing the differentiation phase 
(Figure IV). The more oxidized status of proliferating cells may 1) induce apoptosis, 
which favors tissue remodeling, or 2) activate redox-sensitive factors inducing the 
transcription of genes that encode enzymes involved in glutathione synthesis and 
GSSG recycling (glutathione reductase). This last event will shift the redox potential 
toward reduced state, this will lead to the start of a new cell cycle (38, 58). 
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Figure IV: Alteration of redox potential moves cells through different biological 
stages. 
I.F. Why preterm infant is more susceptible to oxidative stress 
Fetal development occurs in a hypoxic environment. At birth the oxidative 
load is sharply increased. At the same time, oxygen demands increase abruptly. 
Compared to full term infants who easily adapts to this transition, preterm infants’ 
transition from the intra- to extra-uterine environment carries many risks. Among the 
reasons why the preterm infant is more likely to experience oxidative injury than 
more mature newborns are the following (Figure V):  
1- Enzymatic defenses against oxidative stress are still poorly developed. 
Frank and Groseclose measured antioxidant enzyme activities (superoxide dismutase, 
catalase and glutathione peroxidase) in lungs during prenatal, newborn, and postnatal 
periods of rat development and demonstrated a sharp increase (110 % to 200%) just 
prior to term birth and a continued rise after birth (72, 73). These findings suggest 
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that the fetal lung is programmed to increase these enzymes as term approaches in 
preparation for the increased oxidation associated with atmospheric air breathing, 
with its relatively high O2 concentration (72, 74). Available human data suggested 
that human fetal lung has the same programmed increase of antioxidant enzymes as 
gestation progresses (75).  
2- Non enzymatic antioxidant defenses (vitamin E, vitamin C, glutathione, 
etc.) are also deficient as they are mainly transferred from the maternal to fetal 
circulation in the later part of the third trimester (76-78).  
3- The preterm infant is often exposed to high load of oxidant molecules as 
oxygen and total parenteral nutrition (79); and  
4- The fetus and premature infant are also susceptible to inflammation and 
infection that may lead to increased oxidative stress (32). 
 
Figure V: Causes of increased risk of oxidative stress in preterm infants. 
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I.G. Association between oxidative stress and BPD 
Northway et al. coined the term “bronchopulmonary dysplasia”, in 1967, to describe 
findings of pulmonary complications following respiratory therapy for hyaline 
membrane disease in preterm infants. Northway et al. believed the critical factor to be 
exposure to an inspired oxygen concentration > 80% for longer than 150 hours (20). 
This was quickly related to free radicals injury and the inability of preterm infants to 
increase their antioxidant capacity (80). Some years later, Saugstade et al. suggested 
that it is not only hyperoxia, but also oxidative stress per se, that might be a 
contributing factor in the development of BPD (27). 
Even with recent advances in neonatal medicine including prenatal steroids, 
surfactant replacement therapy and noninvasive ventilation; multiple studies have 
shown that babies who develop new BPD also have elevated markers of oxidative 
stress in the first days or weeks of life before the diagnosis of BPD. These markers 
included more oxidized redox potential , a clinical marker of oxidant stress or 
markers that reflect both protein and lipid peroxidation (81-84). These finding despite 
not proving a casual relation between oxidative stress and BPD, they still highlight 
the pertinence of the question to what extent does oxidative stress contribute to the 
development of BPD. 
In a recent work comparing markers of oxidant stress in premature neonates receiving 
PN with different combinations of multivitamins and Intralipids, Chessex et al. were 
able to demonstrate that preterm infants less than 28 weeks of gestational age who 
exhibited the more oxidized redox potential on day 7 of life had more sever BPD at 
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36 weeks CA (81). This was the first report of redox potential of glutathione in 
extremely preterm infants in the NICU settings. The cell status, proliferation – 
differentiation – apoptosis, varies in function of the redox value (38). A more 
oxidized redox potential value may predispose to a loss of alveoli by apoptosis (85, 
86). As preterm infants are often exposed oxygen and total parenteral nutrition as two 
sources of oxidative stress we sought to document the relation between these two 
major oxidants and the redox potential as well as the development of BPD.
  
 
 
 
II - HYPOTHESIS AND OBJECTIVES 
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II.A. Hypothesis: 
We hypothesize that oxidative stress, caused by oxygen supplement and TPN, early 
in life induces the development of BPD, and that the clinical practices maintaining 
this oxidative stress contribute to the severity of the pathology.  
II.B. Objectives:  
1- To investigate the relation between O2 supplementation and the glutathione 
redox status measured in whole blood all in relation with the development and 
severity of BPD in preterm infants less than 29 weeks of gestational age.  
2- To investigate the relation between PN duration and the glutathione redox 
status measured in whole blood all in relation with the development and 
severity of BPD in preterm infants less than 29 weeks of gestational age.
  
 
 
 
 
III - METHODS AND IV - RESULTS  
Methods and results are described in the following article that will be submitted soon 
to the scientific journal Pediatric Research
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Abstract:  
Introduction: oxygen supplementation and total parenteral solution (TPN) are two 
main clinical practices that sustain oxidative stress. Glutathione is a key molecule that 
detoxifies peroxides resulting in a more oxidized redox potential. We hypothesize 
that O2 supplementation and longer TPN duration are associated with both more 
oxidized redox potential and more severe bronchopulmonary dysplasia (BPD). 
Patients and methods: A prospective observational study including infants of less 
than 29 weeks gestational age. GSH and GSSG from whole blood sampled on day 6-
7 and at 36 weeks of corrected age (CA) were measured by capillary electrophoresis 
and redox potential was calculated using Nernst equation.  BPD was classified 
according to NICHD guidelines.  
Results: There was a significant association between FiO2 ≥ 25% on day 7 of life and 
TPN duration longer than 14 days and both more oxidized redox potential and more 
severe BPD.  TPN duration explained both 15 % of total variation observed in redox 
potential and 42 % of total variation in BPD severity. These associations remained 
significant after adjustment for gestational age and illness severity. The relation 
between the severity of BPD and the redox potential in blood was not significant. The 
statistic power (1-β) to show an effect of redox potential on severity of BPD was 
52%. 
Conclusion: Both redox potential of glutathione and BPD severity are both associated 
with early O2 supplement and TPN. Strategies targeting judicious use of O2 
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supplement and either decreasing the duration or using safer formulation of TPN are 
expected to help reducing BPD.  
Keywords: premature infants, oxygen, total parenteral nutrition, oxidative stress, 
redox potential, and bronchopulmonary dysplasia. 
Abstract word count: 248 
Body of manuscript word count: 2920 
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Introduction:  
Advances in perinatal and neonatal medicine over the last few decades resulted in 
marked increase in survival after extremely premature birth (1). Survival of these 
vulnerable infants led to increased incidence of prematurity related diseases. 
Currently, bronchopulmonary dysplasia (BPD) has been proposed the most common 
chronic lung disease in infancy and carries extremely high costs (2). The etiology of 
bronchopulmonary dysplasia appears to be multi-factorial but the oxidative stress 
seems a common point (3-10). Clinical practices that can sustain a major oxidative 
stress are oxygen supplementation and TPN. 
Birth is a major transition from relative hypoxic intrauterine environment where 
arterial pressure of O2 (PaO2) is around 25 mm Hg to oxygen rich extra-uterine 
environment with PaO2 around 75 mm Hg. This means that even 21% O2 is 
considered supra-physiologic for preterm infants and is associated with marked 
increase in total reactive oxygen species burden (11). Furthermore, many preterm 
infants will need supplemental oxygen due to hyaline membrane disease. Under 
conditions of hyperoxia, there is marked increase in the rate of reactive oxygen 
species production with increasing O2 tension (12). In human as well as in animal 
model, oxygen supplement seemed to play an important role in the development of 
bronchopulmonary dysplasia (3, 13-22).   
Parenteral nutrition allows administration of amino acids, dextrose, vitamins, 
electrolytes and lipids. Almost all preterm infants will need parenteral nutrition 
whenever enteral nutrition is not possible. Interaction between reducers such as 
polyunsaturated fatty acids, several amino acids and vitamin C and a strong oxidant 
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as dissolved oxygen generates oxidant molecules. These molecules include aldehydes 
and hydroperoxides derived from lipid peroxidation and hydrogen peroxide (H2O2) 
from ascorbic acid (23-25). While the role of TPN in the development of 
bronchopulmonary dysplasia is poorly understood in preterm infants (26, 27) , the 
low alveoli level observed in PBD (28, 29) is reproduced in animals model infused 
with total parenteral nutrition (TPN) (30, 31). This was explained by higher rate of 
apoptotic events (30). 
Using oxidative stress markers, Chessex P. et al have recently reported a significant 
relation between the severity of BPD and the redox potential of glutathione measured 
in whole blood at one week  (9). Infants with the more severe stage of BPD had the 
more oxidized redox. The intracellular redox environment is known to be a major 
regulator of cellular cycle, from proliferation toward apoptosis; an oxidized status 
favors apoptosis (32, 33). Chessex P. et al suppose that glutathione redox potential 
value observed in whole blood reflects that of the lung. However, newborn animal 
model of light exposed TPN did not support this statement. Indeed, in these animals, 
light exposed TPN induced a more oxidized redox potential in blood whereas lung 
redox potential was more reduced (31). Therefore measurement of the redox potential 
in the whole blood may not reflect that in the lung tissue. 
We hypothesize that oxidative stress early in life induces the development of BPD, 
and that the clinical practices maintaining this oxidative stress including O2 
supplement and TPN contribute to the severity of the pathology. Therefore, the aim 
of the study was to assess the relations between the two mains sources of oxidant, 
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oxygen supplement and TPN, and redox potential of glutathione, all in relation with 
the severity of BPD in infants less than 29 weeks of gestational age.  
Patients and methods:  
This prospective observational study included all infants less than 29 weeks admitted 
to the neonatal intensive care unit (NICU) before 24 hours of life between August 
2010 and July 2011. Only infants with congenital malformations were excluded. A 
written informed consent was obtained before enrolling subject to have their redox 
potential of glutathione measured on day 6-7 and at 36 weeks of CA (group C). To 
ensure that the studied group C represents the whole studies population, clinical data 
collection included all infants admitted to the NICU during that period (group A) as 
shown in figure 1 and both groups were compared.  The study protocol was approved 
by the Research Ethics Board of the CHU Sainte-Justine with registration number 
2792. 
Local NICU practices 
Oxygen supplementation guidelines:  
Oxygen saturation is continuously measured in all infants. Target O2 saturation was 
set between 85 to 92 % for infants who need supplemental O2. 
TPN and enteral nutrition guidelines:  
Total parenteral nutrition is prescribed in the first day of life at 80 ml/kg/day and 
increased 10-20 ml/kg/day till to achieve 150 ± 10 ml/kg/day. Amino acids 
(TrophAmine®) are started on day 1 of life at 2.5 g/kg/d then increased 0.5 g/kg/day 
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to achieve 3.5g/kg/day. Lipides (Intalipid® 20%) are started at 1g/kg/day and increase 
by 0.5 g/kg/day to 2.5 mg/kg/day. Enteral feeding is started with minimal enteral 
feeding of 20 ml/kg/day as soon as the medical condition of the infants stabilizes. If 
mother chooses to breast feed her infant a maximum delay of 3 days was permitted to 
have the first maternal breast milk given to the baby otherwise formula milk was 
started. This minimal enteral feeding is kept for 4 days and then a progressive daily 
increase of 20 ml/kg/day was prescribed if infant is tolerating well. According to 
these guidelines TPN duration of 14 days could be considered as baseline minimal 
duration of TPN for this group. 
Bronchopulmonary dysplasia 
BPD was defined according to the joint U.S. National Institute of Child Health & 
Human Development (NICHD)-National Heart, Lung, and Blood Institute (NHLBI) 
workshop (34). This definition allows the evaluation of BPD severity. Mild BPD was 
defined as the need for supplemental oxygen at 28 days after birth but not at 36 
weeks’ CA; moderate BPD, the need for supplemental oxygen at 28 days and at a 
fraction of inspired oxygen (FiO2) < 30% at 36 weeks’ CA; and severe BPD, the need 
for supplemental oxygen at 28 days and, at 36 weeks’ CA, the need for positive 
pressure and/or FiO2 ≥ 30%. In this study, BPD-0 refers to no-BPD, BPD-1 refers to 
mild BPD, BPD-2 refers to moderate BPD and BPD-3 refers to severe BPD. 
Redox potential of glutathione (mV) 
Within 4 min of sampling, aliquots of whole blood (EDTA tube) were homogenized 
in freshly prepared metaphosphoric acid (5% w/v), centrifuged at 10000 rpm for one 
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minute. Pellet and supernatant were separated and stored at −80 °C. Concentrations of 
GSH and GSSG were determined in supernatant fraction after the samples were 
thawed on ice and diluted one in four in water. The sample was injected at 0.5 psi for 
10 sec on a fused-silica capillary (75 μm×50 cm) at 28°C (P/ACE MDQ system from 
Beckman Coulter). The electrophoresis separation was carried out at 18 kV, for 10 
min, using boric acid 75mM+ Bis-TRIS 25 mM, pH 8.4 as buffer; GSH and GSSG 
were detected at 200 nm (31). Between separations, the capillary was pressure-rinsed 
at 20 psi with 0.1 M NaOH (5 min), water (2 min) and running buffer (5 min). 
Standard curves of GSH (0 to 100 μM) and GSSG (0 to 10 μM) were used for 
quantification. The redox potential was calculated from the Nernst equation (25 °C, 
pH 7.0) (32). 
Statistical analysis  
Data were summarized as proportions, means with standard error of the mean (SEM), median 
with 25th and 75th percentiles or as frequency distribution. The comparisons were 
performed by ANOVA or factorial ANOVA after verification of homoscedasticity by 
the Bartlett’s χ2 test. In case of significant heterogeneity of variance, data were 
logarithmically transformed to meet the homoscedasticity. Because no mathematical 
transformation satisfied the Bartlett’s χ2 test for the comparison of FiO2 values 
observed at 7 days of life in function of severity of BPD, the Chi-squared test has 
been used to compare the liaison between the number of infants with FiO2 ≥ 25% and 
the severity of BPD. All comparisons were orthogonal and the significance was set at 
p < 0.05. The ratio of the sum of squares (from ANOVA table) for a factor (i.e. 
severity of BPD, duration of TPN or FiO2) on the sum of squares for the total 
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variation (x 100) is reported as the percentage of total variation explained by this 
factor.  
Results:  
General characteristics 
Clinical baseline characteristics of group C did not differ from those of group A 
(Table 1). 
The description of parameters measured during this study is shown in figure 2 as 
distributions of frequencies.   
Oxygen and redox potential of glutathione 
The impact of FiO2 on days 7 and 28 as well as at 36 weeks CA on redox potential of 
glutathione is presented in figure 3. The factorial ANOVA reveals that FiO2 ≥ 25% is 
associated with a more oxidized redox potential (F(1,111) = 14.2, p<0.01) 
independently of the postnatal age since the interaction was not significant (F(2,111) = 
0.2). There was no effect of postnatal age (F(2,111) = 0.4). The FiO2 explained 11% of 
the total variation in redox potential.  
Oxygen and severity of BPD  
The relation between FiO2 at 28 days of age and severity of BPD was not analyzed 
because FiO2 ≥ 22% at 28 days of age is part of definition of BPD. However, analysis 
of the relation between FiO2 at 7 days and severity of BPD could be informative. The 
value of FiO2 in function of the severity of BPD has not been evaluated by ANOVA 
since even after mathematical transformation, the heterogeneity of variances 
remained highly significant (Bartlett’s χ2 = 55.1, p<0.01).  Therefore, data were 
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analyzed as non-parametric data using χ2 test. The relation between the severity of 
BPD and the number of infants with a FiO2 ≥ 25% at day 7 of age (Table 2) was 
highly significant with a χ2 = 23.7, p<0.01.  
TPN and redox potential of Glutathione 
The redox potential measured in blood at 36 weeks CA was also influenced by the 
duration of TPN (Figure 4). The ANOVA shows that redox potential in blood at 36 
weeks CA was more oxidized if the infants received TPN for more than 14 days 
(F(1,31) = 5.5, p<0.05). This effect of TPN duration explained 15 % of total variation 
observed in the redox potential.  
TPN and severity of BPD 
The severity of BPD was also influenced by the number of days that the neonates 
remained on TPN (Figure 5). Data from all neonates (22 to 28 weeks of gestation) 
(Figure 5-A) demonstrated that the number of days on TPN was higher in neonates 
with BPD-2 (F(1,84) = 19.9, p<0.01) and more with BPD-3(F(1,84) = 29.5, p<0.01). 
There was no difference between BPD-0 and 1 for the number of days on TPN (F(1,84) 
= 1.1). Forty-two percent of total variation in BPD was explained by the variation in 
TPN duration. This relation between TPN and severity of BPD was independent of 
the gestation age at birth since the same TPN effect is reproduces in groups born at 
22-24 weeks (Figure 5-B), 25-26 weeks (Figure 5-C) and 27-28 weeks of gestation 
(Figure 5-D). The duration of TPN could be the intermediate by which the severity 
of infant disease may cause BPD. In a logistic regression model both the duration of 
   34 
TPN and the SNAPII score were both independent and significant factors in the 
development of BPD with a P<0.01 for both factors. 
Whole blood redox potential of glutathione and BPD 
The last aim was to assess the relation between redox potential of glutathione, 
measured on day 6-7 and at 36 weeks CA, and severity of BPD. The factorial 
ANOVA of data presented in figure 6 reveals a less oxidized redox potential at 36 
weeks CA than at 6-7 days of age (F(1,71) = 5.1, p<0.05). The factor “postnatal age” 
explained 7% of total variation observed in redox potential. The relation between the 
severity of BPD and the redox potential was not significant (F(2,84) = 1.3). The statistic 
power (1-β) to show an effect of redox potential on severity of BPD was 52%. There 
was no interaction between parameters (F(2,84) = 0.3).  
Discussion 
This study indicates that a supplement of oxygen (FiO2 ≥ 25%) or a TPN duration of 
more than two weeks is associated both more oxidized redox potential in blood and a 
greater severity of BPD. However, the link between redox potential measured in 
blood at 6-7 days of age or at 36 weeks CA and the severity of BPD has not been 
demonstrated.  
A similar impact of FiO2 has previously been reported, with similar redox values, to 
occur at one week of age (9). The present study shows that the oxygen effect is 
independent of the postnatal age; suggesting that an oxygen supplement is always 
toxic. Although the oxygen supplement at 28 days and at 36 weeks CA is a part of 
BPD definition, it is surprising that FiO2 ≥ 25% at so early in life, at one week of age, 
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can be associated with the severity of BPD as evaluated at 36 week CA. The 
incidence of infants with FiO2 ≥ 25% increases in function of the severity of BPD: 
9% of infants who do not develop BPD or who develop a mild BPD; 38% for 
moderate BPD; 65% for severe BPD (from Table 2). This suggests that for most 
infants who developed a severe BPD, lung injury could occur in the early days or 
weeks of life.   
The second source of oxidant load is TPN. The redox potential at 36 weeks CA 
shifted toward a more oxidized status after 2 weeks on TPN, a same duration 
observed for the association with the severity of BPD. Because more premature or 
sicker is the infant, the longer will be the need for TPN, the gestational age or the 
illness severity could be a confounding parameter. However, the analyses done on 
grouped data according to gestational age (figure B to D) and the independent effect 
of both TPN and SNAPII score suggest that the impact of TPN on BPD is 
independent of gestational age at birth and severity of illness as estimated by SNAPII 
score. The fact that two weeks on TPN seem enough to induce BPD supports the 
concern raised with oxygen supplementation that lung injury that correlates with the 
severity of BPD could occur in the early days and weeks of life. 
Both high FiO2 and long TPN exposure induced oxidation of redox potential in blood 
and are associated with moderate to severe BPD.  However, redox potentials in blood 
measured on 6-7 days or at 36 weeks CA were not associated with the severity of 
BPD. However, the relatively low statistical power (52%) prevents us from 
confirming that the effect does not exist.  
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With a population similar to ours in number and in prematurity, Chessex et al (9) 
showed this relation between the redox at one week of age and the severity of BPD. 
The main difference between both studies resides in the formulation of TPN used.  
The Chessex’ study compared three groups of neonates receiving similar nutrients but 
that were administered in different modes. All TPN were administered in a binary 
mode that separates the lipid emulsion (LIP) and the amino acids - dextrose (AA). In 
one group, multivitamin preparation (MV) was added to the AA moiety of TPN 
whereas for the two other groups MV were mixed with LIP. The last two groups were 
separated according to light protection of the solution. The animals infused with TPN 
in which MV was mixed with LIP presented a greater alveoli number than the 
animals infused with TPN in which MV was mixed with AA (31). Moreover, the 
impact of FiO2 ≥ 25% on the redox potential was observed only in the group 
receiving TPN in which MV was in AA.   The different TPN modes used by Chessex 
et al (9) were largely different from that used in this study (MV in AA). These 
different modes have different effects on the alveolarization as much as on the redox 
potential.  
In regards of our hypothesis we can conclude that indeed, the clinical practices 
(oxygen supplement and TPN) affect the oxidative stress in premature neonates and 
may contribute to the severity of BPD. However, our results did not confirm that 
redox potential is the mechanism by which oxidative stress contributes to the severity 
of BPD. The relation between redox status in blood and in lung is not proved (31). 
The discrepancy between the impacts of TPN on total variation observed for redox 
potential in blood (15%) and for BPD (42%) suggests that the effect of TPN is 
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mediated through another mechanism than the direct effect on redox potential. Photo-
protection of TPN reduces peroxide concentration in the intravenous solution (35) it 
was also shown to reduce the incidence of BPD (36) or chronic lung diseases (8) in 
premature infants. Peroxides may be suspected to have a direct effect on lung 
development. On the other hand, photo-protection of TPN was found to allow 
enhancing advancement of minimal enteral nutrition preterm infants leading to 
decrease duration of TPN (37). With data from the present study, the beneficial 
impact of photo-protection may be related to a shorter duration of TPN for these 
infants. The beneficial impact of adequate photo-protection (8, 36, 37) suggests that a 
toxic element is generated during photo oxidation of nutrients. 
In conclusion, results from this study indicate that early O2 supplement as well as the 
TPN as currently compounded, are toxic for the lung of preterm infants.  The exact 
mechanisms remain to be discovered. We speculate that strategies targeting judicious 
use of O2 supplement and either decreasing the duration or using safer formulation of 
TPN are expected to help reducing BPD incidence and severity. It is of prime 
importance to find a new way of compounding parenteral nutrition to provide a 
nutritional solution devoid of toxic elements; a TPN that allows the best development 
of the infants without adverse effects. 
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 Group A (n = 
116)  
Group C (n = 
51) 
Gestational age, mean ± SEM (weeks) 26 3/7 ± 1/7 26 4/7 ± 1/7
Birth weight, mean ± SEM (gram) 867 ± 21 846 ± 23  
Apgar score at 5 minutesa 6 (5 - 7) 6 (5 - 8) 
SNAP - II score, mean ± SEM 19 ± 1 19 ± 2 
Sex    
       Female, n (%) 49 (42%) 21 (41%) 
       Male, n (%) 67 (58%) 30 (59%) 
IUGR, n (%) 24 (21%) 8 (16%) 
Vaginal delivery, n (%) 41 (35%) 17 (33%) 
Antenatal steroid    
       Complete course, n (%) 60 (52%) 26 (51%) 
       Incomplete course, n (%) 44 (38%) 23 (45%) 
Suspected chorioamnionoitis, n (%)        16 (14%) 8 (16%) 
Maternal preeclampsia, n (%)  22 (19%) 7 (14%) 
Maternal diabetes, n (%) 16 (14%) 7 (14%) 
 
Table 1: baseline clinical characteristics of group A and group C showed no 
statistically significant differences. 
a presented as median (25th – 75th percentiles) 
 
 
 
   44 
 FiO2 < 25% FiO2 ≥ 25% 
Grade of BPD- 0,1* 29 3 
Grade of BPD-2 10 6 
Grade of BPD-3 15 28 
 
Table 2: Number of infants with FiO2 < 25% and ≥ 25% at day 7 of age in function of 
the severity of BPD. (*BPD 0 and 1 grouped together due to very few infants with 
FiO2 ≥ 25%) 
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Figure 1. Participant flow.  
* These 3 infants did not have clinically indicated samples at 36 weeks of corrected 
age. # 2 samples were stored in -20 instead of – 80 so results were excluded. 
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Figure 2: Distributions of frequencies of the parameters measured during this study 
(group A). 
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Figure 3: The impact of FiO2 on days 7 and 28 days as well as at 36 weeks CA on 
redox potential of glutathione. The redox potential of glutathione is more oxidized in 
infant with FiO2 ≥ 25% on days 7, 28 and at 36 weeks of corrected age. 
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Figure 4: The relation between the duration of TPN and the redox potential of 
glutathione at 36 weeks CA.  The redox potential of glutathione is more oxidized if 
the infants received TPN for more than 14 days.  
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Figure 5: A. In the group A, Increased duration of TPN is associated with increased 
severity of BPD. This relation remained significant in different subgroups of 
gestational age at birth (B. 22-24 weeks, C. 25-26 weeks, D. 27-28 weeks). 
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Figure 6: The relation between the severity of BPD and the redox potential on day 6-
7 and at 36 weeks CA was not significant.  
 
 
 
 
 
 
  
 
V - DISCUSSION 
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This study tested the hypothesis that oxidative stress, caused by oxygen supplement 
and TPN, early in life contributes to the severity of BPD. Our data demonstrated that 
indeed both FiO2 ≥ 25% as well as TPN for > 14 days are associated with more 
oxidized redox potential and more severe BPD. In our cohort there were no 
significant correlation between the redox potential and the severity of BPD. Here I 
will discuss some important points that could not be discussed in the manuscript due 
to editorial limitations:  
V.A. Exposure to oxidants early in life and protracted oxidative stress: 
 In our cohort infants who were exposed to FiO2 ≥ 25% on day 7 of life had 
significantly more oxidized redox potential, even after few weeks, at 36 weeks of CA. 
This reveals a protracted oxidative stress that lasts for several weeks. Similar 
prolonged oxidative stress was reported in a randomized controlled study by Vento, 
M. et al who demonstrated a decreased GSH/GSSG ratio after 4 weeks of life in 
infants who were resuscitated in 100% oxygen for few minutes versus those who 
were resuscitated in room air (87). Others have described this prolonged oxidative 
stress after short oxidant event has stopped in myocardial infarction model (88).This 
phenomenon needs to be explored to define the mechanism of such prolonged effect. 
 
V.B. Why choosing the redox potential as an oxidative stress marker? 
Choosing the marker of oxidative stress is an important part of any work discussing 
this subject. As discussed in the introduction (page 9) oxidative stress includes two 
different mechanistic pathways of oxidative damage namely the macromolecular 
damage (caused mainly by radical oxidants) and the disruption of redox signaling 
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(caused mainly by nonradical oxidants) (45). Biological systems generate more non 
radical oxidants than free radicals (41). In the presence of free radical scavenging 
enzymes like SOD, radical scavenging chemicals like vitamins C and E, and very 
high protein concentration in biological systems; free radical chain reactions are 
nearly completely prevented. The nonradical oxidants (like H2O2) however represent 
a major oxidant burden. They contribute to disease pathology by disruption of redox 
signaling and control mechanisms (40). We have chosen the use the redox potential 
as surrogate of oxidative stress due to the major role of glutathione in detoxifying 
nonradical oxidants (through glutathione oxidase enzyme reaction) and its role as a 
major determinant of cell redox status which controls the cell cycle and modifies 
different enzymatic activities (38-40, 45, 58).  
 
V.C.  If BPD is related to oxidative stress, why studies using different 
antioxidants had very limited impact on BPD? 
 Understanding the nature, quantitative importance and mechanism of action of 
oxidants as well as antioxidants is very important milestone if one would like to 
target the right intervention aiming to decrease or prevent oxidative stress and its 
complications.  
An important example is the use of CuZn superoxide dismutase in mechanically 
ventilated preterm infants to reduce the risk of BPD (89-91). A recent Cochrane 
review concluded that the use of superoxide dismutase to prevent chronic lung 
disease of prematurity is not recommended (92). As discussed in the introduction 
section SOD plays a very important role by reducing the free radical anion 
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superoxide in oxygen and hydrogen peroxide that will be reduced in water by catalase 
or GPx. That means in these studies all infants in the intervention group had very 
effective defense against radical oxidants with the SOD but were exposed to higher 
load of nonradical oxidants (hydrogen peroxide) produced by the SOD. Knowing that 
these preterm infants have deficient glutathione oxidase and catalase systems it will 
be expected that they will experience a more oxidized redox potential and will still be 
prone to BPD.  
The trials to supplement TPN with either cysteine or N-acetycysteine to help 
establishing good glutathione reserve and ameliorate the antioxidant defenses and 
prevent BPD are another example. In a recent Cochrane review including 6 studies, 
the effect of N-acetylcysteine supplementation on death and bronchopulmonary 
dysplasia at 36 weeks corrected age was available in 391 infants (194 in the treatment 
group and 197 in the placebo group). N-acetylcysteine supplementation did not 
significantly affect the risk of death, the risk of bronchopulmonary dysplasia or the 
risk of combined outcome death or bronchopulmonary dysplasia (RR 1.04, 95% CI 
0.85 - 1.27) (93). The study by Lavoie JC et al demonstrated that it is not the 
availability of cysteine but the cysteine uptake that appears to be the limiting step 
explaining the reported low levels of glutathione in premature infants. In this study 
cysteine uptake, which was found to be immature in this population, was shown to be 
responsible for 78% of the variation in glutathione content (94). In the light of these 
finding we cannot presume that cysteine supplement will automatically lead to 
increase intracellular glutathione.  Considering these finding the results of the 
Cochrane review will not be surprising 
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V.D. The impact of the used BPD definition on the results of this study: 
Our study objective was to study the effect of two major oxidants frequently used in 
the NICU with both the redox potential of glutathione as a marker of oxidative stress 
and the severity of BPD. The severity of BPD was defined using the NICHD 
classification (9). With this definition we could not find a significant relation between 
the redox potential measured on day 6-7 or at 36 weeks and the severity of BPD. Will 
this finding remain the same if our study was looking to the development of BPD as a 
dichotomous outcome according to the classic definition (7, 8) which is “the 
requirement for additional oxygen at a corrected postnatal gestational age of 36 
weeks in infants less than 1,500 g of birth weight”? The answer is no. In this case 
there is a significant association between more oxidized redox potential and BPD 
(Figure VI).  
 
Figure VI: When using the classic definition of BPD there is a significant correlation 
between more oxidized redox potential and BPD. 
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This relation between more oxidized redox potential and BPD could be viewed as a 
cause-effect association if we consider that the more oxidative stress resulted in the 
BPD development as supported by animal model using O2 supplement or TPN to 
develop BPD (86, 95, 96). Alternatively, this more oxidized redox in the BPD group 
could be viewed as a consequence of receiving O2 supplement. Animal model study 
could permit to determine whether this is a cause-effect relationship or not.  
 
V.E. The impact of normal development of antioxidant defenses on the results of 
this study: 
Our population included infant between 22 and 28 weeks of gestational age. Animal 
model (72, 74)as well as human (75) available data suggest that the fetal lung is 
programmed to increase antioxidant enzymes as term approaches in preparation for 
the increased oxidation associated with atmospheric air breathing, with its relatively 
high O2 concentration. 
There are no available data on redox potential measurement in this age group. Redox 
potential of these infants on day 6-7 could be affected by this chronological 
maturation raising the question if this group is homogenous. We were not able to 
perform our analyses according to GA strata due to sample size limitations.  
When we tried to test the effect of performing this analysis on a more homogenous 
subgroup (infants of 26-27 weeks of gestational age), the relation between the redox 
potential on day 6-7 and the development of BPD approached significance with P = 
0.058.  
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It will be of interest to have a larger sample size with more infants in each gestational 
age to be able to adjust for the effect of GA. 
 
V.F. Strengths and Limitations  
V.F.1. An Observational prospective cohort study:  
In this work, an observational prospective cohort design was used. This was the most 
appropriate design in human neonate context as exposure to O2 and TPN should be 
guided only by individual infant need in conformity with the current clinical 
guidelines.  
We aimed to study the effect of both O2 and TPN on the redox potential as a marker 
of oxidative stress and BPD. In this case the casual inference was enhanced by 
temporal sequence, prior evidence and biologic plausibility. However, the relation 
between redox potential and BPD was compromised by incapacity to stratify or adjust 
by the gestational age (due to sample size limitation) in the case of redox potential on 
day 6-7 and by the lack of temporal sequence in the case of redox potential at 36 
weeks corrected age.  
 
 V.F.2. Study population and sample: 
We aimed to study the relation between O2 and TPN, redox potential and BPD in 
infants less than 29 weeks gestational age. This selection was justified by the high 
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risk of exposure to both O2 and TPN with limited antioxidant capacity. To insure that 
our sample represent the whole studied population we used all admitted infants with 
that gestational age during the whole study period as a comparator. All the 
demographic data and initial severity of illness score were similar between our 
sample and the whole study population.  
 V.F.3. The effect of level III NICU dynamics on our results: 
As a referral center our unit policy is to transfer all stable infants to their local 
hospitals, this lead to the noticed small number in both no BPD and mild BPD 
categories. To be able to perform severity of BPD analyses we were obliged to 
combine these 2 categories (no BPD and mild BPD) together to get a reasonable 
number in this group. In our clinical setting it will be challenging to have measures of 
redox potential from enough infant with no or mild BPD and this fact needs to be 
addressed in further studies.   
V.G. Future works 
V.G.1. On the same cohort: 
Parenteral nutrition is contaminated by peroxides including the ascorbylperoxide 
which cause an oxidized redox potential in premature infants. Previous works from 
the laboratory of Dr Jean-Claude Lavoie suggest that ascorbyperoxide is associated 
with perturbation of alveolar development (52, 85). We collected urine samples from 
group C on day 3, 5 and 7 of life as well as at 36 weeks of corrected age. We will 
investigate the relation between the ascorbyperoxide in the urine and the redox 
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potential as well as the BPD in preterm infants of less than 29 weeks of gestational 
age. 
 V.G.2. Future combined animal and human study project: 
Our work team with other collaborators obtained a CIHR fund (CIHR 246505) to 
perform a larger scale study combining the animal model with a clinical study. The 
objective of this study is to understand the biochemical mechanisms of the relation 
between the ascorbylperoxide, oxidized redox potential and BPD in order to develop 
a nutritional alternative that could help in decreasing the incidence and severity of 
BPD. The specific objectives of this project are:  
1- Validate that, in the animal model, the effect of the ascorbyperoxide on the 
alveolar development could be through perturbation of the glutathione system leading 
to oxidized redox potential and induction of alveolar apoptosis in the lung. This 
objective will be achieved by measuring in the newborn guinea pigs infused with 
increasing doses of ascorbyperoxide, the alveolarization index, apoptosis, glutathione 
redox state (potential redox, glutathione peroxidase and reductase, activation of 
transcription factors Nrf2 and NFκΒ) in relation to the level of ascorbyperoxide in the 
lung and the urine. 
2- Test, in the animal model, 2 suggested alternatives to prevent the alveolar 
development perturbation by the TPN: 
 a- The addition of glutathione to the TPN in order to ameliorate the 
glutathione defense system and prevent the oxidative stress and the alveolar 
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hypoplasia. This objective will be achieved by measuring the alveolarization index, 
apoptosis, the glutathione system and the pulmonary and urinary level of 
ascorbyperoxide in guinea pigs receiving TPN supplemented or not with glutathione. 
 b- Using vitamin C-2Phosphate as an alternative to vitamin C. This form is 
stable in vitro and will not form the ascorbyperoxide molecule and could help 
avoiding alveolar hypoplasia by preventing ascorbyperoxide formation. This 
objective will be achieved by measuring the alveolarization index, apoptosis, the 
glutathione system and the pulmonary and urinary level of ascorbyperoxide and 
vitamin C in guinea pigs receiving TPN containing either vitamin C-2Phosphate or 
vitamin C. 
3- Confirm the association between the ascorbylperoxide and BPD in premature 
infants less than 32 weeks of gestational age using the correlation between the levels 
of urinary ascorbylperoxide, the redox potential with the severity of BPD. In this 
study gestational age is considered as co-variable, sex and FiO2 concentration will be 
considered as variable and sample size for ANCOVA analysis is estimated at 240 
infants. 
  
 
 
V - CONCLUSION 
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In preterm infants less than 29 weeks of gestational age, early exposure to O2 (≥25% 
on day 7 of life) and longer duration of TPN (more than 14 days) are associated with 
more oxidized whole blood redox potential at 36 weeks and more severe BPD. More 
efforts should be directed towards strategies targeting judicious use of O2 supplement 
and either decreasing the duration or using a safer formulation of TPN. There is an 
urgent need to find a new way of compounding parenteral nutrition to provide a 
nutritional solution without toxic elements; a TPN that allows the best development 
of these infants without adverse effects. 
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